Zelboraf (Vemurafenib): What It Is and What to Expect

BRAF is a protein that carries a growth message from the cell surface toward the nucleus. In about half of melanomas the BRAF gene is changed at position 600. The most common change is called V600E. The altered protein sends the growth message whether or not anything asked for it.

Vemurafenib is a kinase inhibitor built to fit that altered protein. It does not fit the normal one nearly as well. That is the point of the drug, and it is also the reason for the rule in the next section.

Zelboraf is the brand name. Vemurafenib is the generic name.

The label is unusually strict about sequence. BRAF V600E has to be confirmed in tumor tissue, using an FDA-approved test, before the first dose.

There is a laboratory reason. In cells whose BRAF gene is normal, this class of drug can do the reverse of what is wanted. It can switch the growth pathway on and push cells to divide. So the test is not paperwork. It is a safety step. Tissue testing is covered in more depth under biomarker testing.

The dose is 960 mg by mouth every 12 hours. That is four 240 mg tablets each time. Food does not matter. A missed dose can be taken up to four hours before the next one is due. Those are the label figures. Take what your melanoma team has written on your prescription, and ring them before changing anything.

Take the number of tablets your own melanoma team prescribed. They cut the amount when side effects demand it, and the label sets out how far it can be reduced before the drug is stopped instead.

The label has a fixed ladder for cutting back. There are two permitted steps down, and it does not go lower. If someone cannot tolerate the smaller of them, the drug is stopped rather than shaved further.

Other medicines shift blood levels. The antifungal itraconazole raised exposure by about 40 percent in a study. The antibiotic rifampin lowered it by about 40 percent. The label says to avoid strong CYP3A4 inhibitors and inducers. Where an inducer cannot be avoided, it directs adding one extra tablet.

This matters for anyone reading an older page. NCI's melanoma treatment summary states that three BRAF plus MEK inhibitor combinations improved both progression-free and overall survival compared with a single BRAF inhibitor. Vemurafenib plus cobimetinib is one. Dabrafenib plus trametinib and encorafenib plus binimetinib are the others.

The same summary notes that vemurafenib on its own did not improve relapse-free survival after surgery in the BRIM8 trial. So single-agent vemurafenib is a narrower option than the drug's own label alone suggests. Melanoma treatment now usually starts from a combination or from immunotherapy.

This is the effect that surprises people most. Blocking BRAF in a tumor can wake up separate skin cells that carry other mutations.

In the first randomized trial, 24 percent of people on vemurafenib developed a cutaneous squamous cell carcinoma or a keratoacanthoma. In the comparison group taking dacarbazine, under 1 percent did. The middle time to the first one was 7 to 8 weeks. About a third of those who had one had another, roughly 6 weeks later.

These growths are cut out, and the label says treatment continues without a dose change. It also requires skin exams before starting, every two months during treatment, and for up to six months after stopping. Squamous cell cancers of the head and neck that are not in the skin can also occur, so the label asks for checks of those areas too.

In the melanoma trials, the reactions reported in 30 percent or more were joint pain, rash, hair loss, fatigue, sun sensitivity, nausea, itching and skin papillomas. The most common severe ones were squamous cell skin cancer and rash.

Sun sensitivity is not a small matter here. The label asks for staying out of the sun, covering up, and using a broad-spectrum UVA and UVB sunscreen and lip balm of SPF 30 or higher.

Other listed risks include severe allergic reactions, Stevens-Johnson syndrome, a lengthened QT interval on the heart tracing, and liver injury. Liver tests are drawn before starting and monthly. Radiation given before, during or after vemurafenib can flare, and fatal cases have been reported when internal organs were in the field. Dupuytren's contracture, a thickening in the palm that bends the fingers, has also been reported.

The second indication is easy to misread as a blood cancer. It is not quite that. Erdheim-Chester disease is a rare build-up of histiocytes, a type of immune cell, in bone and other organs.

The label's evidence here is small and worth knowing: 22 people, treated for a median of about 14 months. More than half had joint pain, a blotchy rash, hair loss, fatigue, a lengthened QT interval and skin papillomas. Adverse reactions led 32 percent of them to stop the drug permanently.

Zelboraf has no boxed warning, and its contraindications section reads "None." Neither means the drug is gentle. It means the risks are handled through the monitoring above rather than by ruling people out in advance.

The current label sits at DailyMed. The maker must keep it up to date. A pharmacist can check it against one person's other prescriptions, which a general page cannot do. Sudden trouble breathing, chest pain, fainting, heavy bleeding, swelling of the face or throat, or a rash that starts to blister or peel are emergencies whatever the drug: call 911 rather than waiting for a call back. What the drug is meant to achieve in one case belongs in the treatment plan.

• https://www.cancer.gov/about-cancer/treatment/drugs/vemurafenib
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763
• https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq